THE IMPACT OF COVID-19 INFECTION AND TREATMENT ON MIGRAINE DISABILITY AND PAIN SCORES

Abstract

Aim: This study aimed to investigate the effects of favipravir used for treating Covid-19 infection and other infectious diseases, on migraine severity and frequency through VAS (Visual Analog Scale), MIDAS (Migraine Disability Assesment Scale). Methods: The study was planned retrospectively, from January 2020 to September 2021, to evaluate patient demographical features who have received migraine diagnosis before or after Covid-19 infection (3 months) admitted in the neurology outpatient clinics of Alanya Alaaddin Keykubat University Training and Research Hospital. Findings: From 70 patients in total 12 (17.1%) of the patients involved in the study were male, while 58 (82.9%) were female. 32 (45.7%) of patients used favipravir and 38 (54.3%) did not use Favipravir. The number of migraine attacks after Covid-19 were found significantly lower than the average of the VAS and Midas scores before covid infection. The average number of migraines before Covid-19 infection was 4.31 ± 2.80, which was found as 3.54 ± 3.07 after the Covid-19 infection. The effect of favipravir use on headache parameters before Covid-19 and after Covid-19 for patients were found similar (p> 0.05). Conclusion: Our study, provides valuable data on the effects of infection and/or isolation on migraine frequency and severity, possibly exerting a prophylactic effect for migraine type headaches.